A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms OPTIC
- Sponsors ARIAD Pharmaceuticals
- 01 Jul 2019 Planned End Date changed from 31 Dec 2022 to 30 Sep 2021.
- 01 Jul 2019 Planned primary completion date changed from 31 Dec 2020 to 13 May 2020.
- 30 May 2019 Status changed from recruiting to active, no longer recruiting.